Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Drug resistant (DR) tuberculosis: current scenario
3. Multi drug resistant tuberculosis
4. Extensively drug resistant tuberculosis
5. Importance of understanding DR mechanisms
6. Diagnosis of drug resistance
7. Technical challenges of conventional DST
8. WHO policies
9. LPA performance in isolates and clinical samples
10. Main anti-TB drugs and mechanisms of action
11. Mechanisms of drug resistance acquisition
12. Development of drug resistant tuberculosis
13. Drug resistant TB is a man-made disease
14. Clinical relevance of drugs resistance
15. Mechanisms of drug resistance in tuberculosis
16. Isoniazid: targeting mycolic acid biosynthesis
17. Ethionamide
18. ethA mutations and ethionamide resistance
19. Other genes correlated to ethionamide resistance
20. Rifampicin
21. Low concordance of "rare mutations": MGIT DST
22. Pyrazinamide - Mechanism of action
23. Pyrazinamide - Mechanisms of resistance
24. Ethambutol
25. Role of point mutations in outcome prediction
26. Fluoroquinolones
27. Second line injectable drugs
28. Fluoroquinolones & injectables: commercial tests
29. PAS
30. Linezolid
31. Point mutations and drug resistance
32. Conclusions
33. Acknowledgements

Topics Covered

• Drug resistant tuberculosis epidemic
• Mechanisms of drug resistance in M.tuberculosis
• Mechanisms of drug resistance to first and second line antitubercular drugs
• Considerations on currently available molecular tests for the diagnosis of drug resistant tuberculosis

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Cirillo, D. (2013, February 28). Molecular mechanisms of drug resistance in M. tuberculosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/BJMX8747.
Export Citation (RIS)

Publication History

• Published on February 28, 2013

Financial Disclosures

• Dr. Daniela Cirillo has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.